Skip to main content
  • Editorial: Hyperbaric Oxygen Therapy Post-Primary PCI: Where Is It Going?

    In a randomized controlled trial of hyperbaric oxygen therapy (HBOT) initiated 3 days following primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI), the HBOT strategy was found to be feasible and safe [1]. When compared to baseline (post-PCI) single-photon emission computed tomography (SPECT) perfusion study, the number of underperfused segments at 3 weeks was significantly reduced (47.1 ± 14.6% vs. 33.7 ± 16.2%, respectively, with p = 0.039). This significant beneficial effect was not observed in the control arm. The authors suggested a multi-center randomized clinical trial to further delineate the efficacy of immediate HBOT after primary PCI.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details